J. Pich

发表

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

V. Wong, H. D. de Koning, F. Lammert, 2021, Hepatology.

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

D. Podzamczer, J. Gatell, E. Martinez, 2012, AIDS.

Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

D. Podzamczer, B. Clotet, J. Gatell, 2009, Journal of acquired immune deficiency syndromes.

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

D. Podzamczer, B. Clotet, J. Miro, 2009, Journal of acquired immune deficiency syndromes.

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

D. Podzamczer, E. Negredo, E. Martinez, 2014, HIV medicine.

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.

R. Andrade, P. Kamath, J. Trebicka, 2019, The lancet. Gastroenterology & hepatology.

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL ASSESSING SAFETY OF TWO DIFFERENT DOSES OF SIMVASTATIN IN COMBINATION WITH RIFAXIMIN IN DECOMPENSATED CIRRHOSIS

R. Andrade, M. Bernardi, P. Kamath, 2019 .

Ginès P. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis

R. Andrade, M. Bernardi, P. Kamath, 2022 .

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

D. Podzamczer, M. Plana, A. Cruceta, 2010, AIDS research and human retroviruses.

A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

J. Miro, J. Gatell, J. Mallolas, 2007, Revista clinica espanola.

Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.

J. Gatell, E. Martinez, J. Pich, 2013, The Journal of antimicrobial chemotherapy.

LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

H. D. de Koning, F. Lammert, T. Karlsen, 2022, BMC Public Health.

Role of a research ethics committee in follow-up and publication of results

J. Rodés, X. Carné, J. Pich, 2003, The Lancet.

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial.

J. Blanco, B. Trinité, L. Leal, 2022, medRxiv.

ENDPOINTS AND DESIGN OF CLINICAL TRIALS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: POSITION PAPER OF THE LIVERHOPE CONSORTIUM.

G. Nicolao, A. Forner, P. Kamath, 2020, Journal of hepatology.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Felipe García, A. León, J. Mallolas, 2016, The Journal of antimicrobial chemotherapy.

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B

C. Brander, Felipe García, M. Plana, 2019, Vaccines.

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.

D. Podzamczer, E. Negredo, J. Gatell, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

D. Podzamczer, J. Gatell, J. Mallolas, 2015, The Lancet. Infectious diseases.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

J. Gatell, E. Martinez, M. Larrousse, 2010, AIDS.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Felipe García, A. León, J. Mallolas, 2016, The Journal of antimicrobial chemotherapy.

Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial

Felipe García, M. Plana, J. Gatell, 2021, Frontiers in Immunology.

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection

J. Martinez-Picado, C. Brander, Felipe García, 2018, AIDS.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

Felipe García, M. Plana, G. Pantaleo, 2011, Vaccine.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization

Felipe García, M. Plana, J. Gatell, 2017, PloS one.

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

B. Clotet, J. Martinez-Picado, C. Brander, 2015, The Journal of antimicrobial chemotherapy.

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

D. Podzamczer, J. Gatell, J. Mallolas, 2010, AIDS.

LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

H. D. de Koning, T. Karlsen, G. Pera, 2022, BMC Public Health.

Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

H. D. de Koning, T. Karlsen, G. Pera, 2023, BMC Public Health.

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization

Felipe García, M. Plana, J. Gatell, 2018, PloS one.

Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.

J. Gatell, E. Martinez, J. Pich, 2012, AIDS research and human retroviruses.

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults

J. Gatell, J. Mallolas, F. Vidal, 2008, AIDS.

Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study

V. Wong, T. Karlsen, G. Pera, 2023, The Lancet.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

J. Gatell, E. Martinez, M. Larrousse, 2010, AIDS.